ClearPoint Neuro is progressing toward expedited FDA reviews for its therapies.
3 reports, 3 independent
Updated Aug 13
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 3
- Developments
- 2
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ClearPoint Neuro is progressing toward expedited FDA reviews for its therapies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.ClearPoint Neuro is moving toward expedited FDA reviews.1 source
ClearPoint Neuro received FDA authorization for the SmartFlow Neuro Cannula device and began commercial infusions.1 source
Keep exploring
The entities involved
-
ClearPoint Neuro (United States)
company in Irvine, United States
Nothing else this week.
- FDA
Related events
- Adam Craig reported positive results that could support FDA approval for a treatment.
- FDA failed to update warning labels despite confirmed risks associated with a product.
- FDA placed a clinical hold on the drug application submitted by Bright Minds Biosciences Inc.
- FDA approval supports NDA submission in Aurora.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
Coverage
Newest first; wire copies grouped- GuruFocus.comClearPoint Neuro Inc (CLPT) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... Total Revenue: $9.2 million for Q2 2025, up 17% from $7.9 million in Q2 2024. Biologics and Drug Delivery
- ZacksClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss o
- ACCESS NewswireClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint N